Opioids for Chronic Noncancer Pain: Prediction and Identification of Aberrant Drug-Related Behaviors: A Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline


      Optimal methods to predict risk of aberrant drug-related behaviors before initiation of opioids for chronic noncancer pain and to identify aberrant behaviors after therapy is initiated are uncertain. We systematically reviewed published literature identified through searches of Ovid MEDLINE and the Cochrane databases through July 2008. Diagnostic test characteristics and accompanying confidence intervals were calculated with data extracted from the studies. Four prospective studies evaluated diagnostic accuracy of risk prediction instruments. Two higher-quality derivation studies found that high scores on the Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1 and the Revised SOAPP (SOAPP-R) instruments weakly increased the likelihood for future aberrant drug-related behaviors (positive likelihood ratios [PLR], 2.90 [95% CI, 1.91 to 4.39] and 2.50 [95% CI, 1.93 to 3.24], respectively). Low scores on the SOAPP Version 1 moderately decreased the likelihood for aberrant drug-related behaviors (negative likelihood ratio [NLR], 0.13 [95% CI, 0.05 to 0.34]) and low scores on the SOAPP-R weakly decreased the likelihood (NLR, 0.29 [95% CI, 0.18 to 0.46]), but estimates are too imprecise to determine if there is a difference between these instruments. One lower-quality study found that categorization as high risk using the Opioid Risk Tool strongly increased the likelihood for future aberrant drug-related behaviors (PLR, 14.3 [95% CI, 5.35 to 38.4]) and classification as low risk strongly decreased the likelihood (PLR, 0.08 [95% CI, 0.01 to 0.62]). Nine studies evaluated monitoring instruments for identification of aberrant drug-related behaviors in patients on opioid therapy. One higher-quality derivation study found higher scores on the Current Opioid Misuse Measure (COMM) weakly increased the likelihood of current aberrant drug-related behaviors (PLR, 2.77 [95% CI, 2.06 to 3.72]) and lower scores weakly decreased the likelihood (NLR, 0.35 [95% CI, 0.24 to 0.52]). In 8 studies of other monitoring instruments, diagnostic accuracy was poor, results were difficult to interpret due to methodological shortcomings, or standard diagnostic test characteristics were not reported. Definitions for aberrant drug-related behaviors were not standardized across studies and did not account for seriousness of identified behaviors. No reliable evidence exists on accuracy of urine drug screening, pill counts, or prescription drug monitoring programs; or clinical outcomes associated with different assessment or monitoring strategies.


      Evidence on prediction and identification of aberrant drug-related behaviors is limited. Although several screening instruments may be useful, evidence is sparse and primarily based on derivation studies, and methodological shortcomings exist in all studies. Research that performs external validation, uses standardized definitions for clinically relevant aberrant drug-related behaviors, and evaluates clinical outcomes associated with different assessment and monitoring strategies is needed.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Adams L.L.
        • Gatchel R.J.
        • Robinson R.C.
        • Polatin P.
        • Gajraj N.
        • Deschner M.
        • Noe C.
        Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients.
        J Pain Symptom Manage. 2004; 27: 440-459
        • Akbik H.
        • Butler S.F.
        • Budman S.H.
        • Fernandez K.
        • Katz N.P.
        • Jamison R.N.
        Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP).
        J Pain Symptom Manage. 2006; 32: 287-293
        • Allan L.
        • Richarz U.
        • Simpson K.
        • Slappendel R.
        Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain.
        Spine. 2005; 30: 2484-2490
        • Atluri S.L.
        • Sudarshan G.
        Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain.
        Pain Physician. 2004; 7: 333-338
        • Belgrade M.J.
        • Schamber C.D.
        • Lindgren B.R.
        The DIRE score: Predicting outcomes of opioid prescribing for chronic pain.
        J Pain. 2006; 7: 671-681
      1. British Pain Society: Recommendations for the appropriate use of opioids for persistent non-cancer pain (the first revised edition). London: The British Pain Society, March 2005

        • Butler S.F.
        • Budman S.H.
        • Fernandez K.
        • Jamison R.N.
        Validation of a screener and opioid assessment measure for patients with chronic pain.
        Pain. 2004; 112: 65-75
        • Butler S.F.
        • Budman S.H.
        • Fernandez K.C.
        • Houle B.
        • Benoit C.
        • Katz N.
        • Jamison R.N.
        Development and validation of the current opioid misuse measure.
        Pain. 2007; 130: 144-156
        • Butler S.F.
        • Fernandez K.
        • Benoit C.
        • Budman S.H.
        • Jamison R.N.
        Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R).
        J Pain. 2008; 9: 360-372
        • Caudill-Slosberg M.A.
        • Schwartz L.M.
        • Woloshin S.
        Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000.
        Pain. 2004; 109: 514-519
        • Chabal C.
        • Erjavec M.K.
        • Jacobson L.
        • Mariano A.
        • Chaney E.
        Clinical criteria, incidence, and predictors.
        Clin J Pain. 1997; 13: 150-155
        • Chou C.
        • Fanciullo G.
        • Fine P.
        • Adler J.
        • Ballantyne J.
        • Davies P.
        • Donovan M.
        • Fishbain D.
        • Foley K.
        • Fudin J.
        • Gilson A.
        • Kelter A.
        • Mauskop A.
        • O'Connor P.
        • Passik S.
        • Pasternak G.
        • Portenoy R.
        • Rich B.
        • Roberts R.
        • Saper J.
        • Todd K.
        • Miaskowski C.
        • for the American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel
        Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.
        J Pain. 2009; 10: 113-130
      2. Chou R, Huffman L. The use of opioids for chronic non-cancer pain: Evidence review. Glenview, IL: American Pain Society, 2009

        • Coambs R.
        A new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain with general medical practice.
        Pain Res Manag. 1996; 1: 155-162
        • Compton P.
        • Darakjian J.
        • Miotto K.
        Screening for addiction in patients with chronic pain and “problematic” substance use: Evaluation of a pilot assessment tool.
        J Pain Symptom Manage. 1998; 16: 355-363
        • Edlund M.J.
        • Steffick D.
        • Hudson T.
        • Harris K.M.
        • Sullivan M.
        Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain.
        Pain. 2007; 129: 355-362
        • Fishbain D.A.
        • Cutler R.B.
        • Rosomoff H.L.
        • Rosomoff R.S.
        Validity of self-reported drug use in chronic pain patients.
        Clin J Pain. 1999; 15: 184-191
        • Fishman S.M.
        • Wilsey B.
        • Yang J.
        • Reisfield G.M.
        • Bandman T.B.
        • Borsook D.
        Adherence monitoring and drug surveillance in chronic opioid therapy.
        J Pain Sympt Manage. 2000; 20: 293-307
        • Fleming M.F.
        • Balousek S.L.
        • Klessig C.L.
        • Mundt M.P.
        • Brown D.D.
        Substance use disorders in a primary care sample receiving daily opioid therapy.
        J Pain. 2007; 8: 573-582
        • Friedman R.
        • Li V.
        • Mehrotra D.
        Treating pain patients at risk: Evaluation of a screening tool in opioid-treated pain patients with and without addiction.
        Pain Med. 2003; 4: 182-185
        • Furlan A.D.
        • Sandoval J.A.
        • Mailis-Gagnon A.
        • Tunks E.
        Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects.
        CMAJ. 2006; 174: 1589-1594
        • Graziotti P.
        • Goucke R.
        The use of oral opioids in patients with chronic nonmalignant pain: Management strategies.
        Med J Austr. 1997; 167: 30-34
        • Gustorff B.
        Intravenous opioid testing in patients with chronic non-cancer pain.
        Eur J Pain. 2005; 9: 123-125
        • Hariharan J.
        • Lamb G.
        • Neuner J.
        Long-term opioid contract use for chronic pain management in primary care practice: A five year experience.
        J Gen Intern Med. 2007; 22: 485-490
        • Harris R.P.
        • Helfand M.
        • Woolf S.H.
        • Lohr K.N.
        • Mulrow C.D.
        • Teutsch S.M.
        • Atkins D.
        Current methods of the third US Preventive Services Task Force.
        Am J Prev Med. 2001; 20: 21-35
        • Hojsted J.
        • Sjogren P.
        Addiction to opioids in chronic pain patients: A literature review.
        Eur J Pain. 2007; 11: 490-518
        • Holmes C.P.
        • Gatchel R.J.
        • Adams L.L.
        • Stowell A.W.
        • Hatten A.
        • Noe C.
        • Lou L.
        An opioid screening instrument: Long-term evaluation of the utility of the pain medication questionnaire.
        Pain Pract. 2006; 6: 74-88
        • Ives T.J.
        • Chelminski P.R.
        • Hammett-Stabler C.A.
        • Malone R.M.
        • Perhac J.S.
        • Potisek N.M.
        • Shilliday B.B.
        • DeWalt D.A.
        • Pignone M.P.
        Predictors of opioid misuse in patients with chronic pain: A prospective cohort study.
        BMC Health Serv Res. 2006; 6: 46
        • Jaeschke R.
        Users' guide to the medical literature, III: How to use an article about diagnostic test, B: What are the results and will they help me in caring for my patients?.
        JAMA. 1994; 271: 703-707
        • Jaeschke R.
        • Guyatt G.H.
        • Sackett D.L.
        Users' guides to the medical literature, III: How to use an article about a diagnostic test, B: What are the results and will they help me in caring for my patients?.
        JAMA. 1994; 271: 703-707
      3. Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch M, Moulin D: Use of opioid analgesics for the treatment of chronic noncancer pain: A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 8:3A–28A, 2003

        • Kalman S.
        • Osterberg A.
        • Sorensen J.
        • Boivie J.
        • Bertler A.
        Morphine responsiveness in a group of well-defined multiple sclerosis patients: A study with iv morphine.
        Eur J Pain. 2002; 6: 69-80
        • Kalso E.
        • Allan L.
        • Dellemijn P.L.
        • Faura C.C.
        • Ilias W.K.
        • Jensen T.S.
        • Perrot S.
        • Plaghki L.H.
        • Zenz M.
        European Federation of Chapters of the International Association for the Study of Pain. Recommendations for using opioids in chronic non-cancer pain.
        Eur J Pain. 2003; 7: 381-386
        • Kalso E.
        • Edwards J.E.
        • Moore R.A.
        • McQuay H.J.
        Opioids in chronic non-cancer pain: Systematic review of efficacy and safety.
        Pain. 2004; 112: 372-380
        • Katz N.
        • Fanciullo G.J.
        Role of urine toxicology testing in the management of chronic opioid therapy.
        Clin J Pain. 2002; 18: S76-S82
        • Lijmer J.G.
        • Mol B.W.
        • Heisterkamp S.
        • Bonsel G.J.
        • Prins M.H.
        • van der Meulen J.H.
        • Bossuyt P.M.
        Empirical evidence of design-related bias in studies of diagnostic tests.
        JAMA. 1999; 282: 1061-1066
        • Mahowald M.L.
        • Singh J.A.
        • Majeski P.
        Opioid use by patients in an orthopedics spine clinic.
        Arthritis Rheum. 2005; 52: 312-321
        • Manchikanti L.
        • Cash K.A.
        • Damron K.S.
        • Manchukonda R.
        • Pampati V.
        • McManus C.D.
        Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables.
        Pain Physician. 2006; 9: 215-225
        • Manchikanti L.
        • Giordano J.
        • Boswell M.V.
        • Fellows B.
        • Manchukonda R.
        • Pampati V.
        Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients.
        J Opioid Manage. 2007; 3: 89-100
        • Manchikanti L.
        • Manchukonda R.
        • Damron K.S.
        • Brandon D.
        • McManus C.D.
        • Cash K.
        Does adherence monitoring reduce controlled substance abuse in chronic pain patients?.
        Pain Physician. 2006; 9: 57-60
        • Manchikanti L.
        • Manchukonda R.
        • Pampati V.
        • Damron K.S.
        • Brandon D.E.
        • Cash K.A.
        • McManus C.D.
        Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?.
        Pain Physician. 2006; 9: 123-129
        • Manchikanti L.
        • Pampati V.
        • Damron K.S.
        • Beyer C.D.
        • Barnhill R.C.
        Prevalence of illicit drug use in patients without controlled substance abuse in interventional pain management.
        Pain Physician. 2003; 6: 173-178
        • Manchikanti L.
        • Pampati V.
        • Damron K.S.
        • McManus C.D.
        Evaluation of variables in illicit drug use: Does a controlled substance abuse screening tool identify illicit drug use?.
        Pain Physician. 2004; 7: 71-75
        • Maruta T.
        • Swanson D.W.
        • Finlayson R.E.
        Drug abuse and dependency in patients with chronic pain.
        Mayo Clin Proc. 1979; 54: 241-244
        • McGinn T.G.
        • Guyatt G.H.
        • Wyer P.C.
        • Naylor C.D.
        • Stiell I.G.
        • Richardson W.S.
        Users' guides to the medical literature XXII: How to use articles about clinical decision rules.
        JAMA. 2000; 284: 79-84
        • Michna E.
        • Jamison R.N.
        • Pham L.-D.
        • Ross E.L.
        • Janfaza D.
        • Nedeljkovic S.S.
        • Narang S.
        • Palombi D.
        • Wasan A.D.
        Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings.
        Clin J Pain. 2007; 23: 173-179
        • Michna E.
        • Ross E.L.
        • Hynes W.L.
        • Nedeljkovic S.S.
        • Soumekh S.
        • Janfaza D.
        • Palombi D.
        • Jamison R.N.
        Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.
        J Pain Sympt Manage. 2004; 28: 250-258
        • Moher D.
        • Pham B.
        • Klassen T.P.
        • Schulz K.F.
        • Berlin J.A.
        • Jadad A.R.
        • Liberati A.
        What contributions do languages other than English make on the results of meta-analyses?.
        J Clin Epidemiol. 2000; 53: 964-972
        • Moore R.A.
        • McQuay H.J.
        Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids.
        Arthritis Res Ther. 2005; 7: R1046-R1051
        • Noble M.
        • Tregear S.J.
        • Treadwell J.R.
        • Schoelles K.
        Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety.
        J Pain Sympt Manage. 2008; 35: 214-228
        • Passik S.D.
        • Kirsh K.L.
        The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain.
        Pain Med. 2003; 4: 186-189
        • Passik S.D.
        • Kirsh K.L.
        • Whitcomb L.
        • Portenoy R.K.
        • Katz N.P.
        • Kleinman L.
        • Dodd S.L.
        • Schein J.R.
        A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy.
        Clin Ther. 2004; 26: 552-561
        • Passik S.D.
        • Kirsh K.L.
        • Whitcomb L.
        • Schein J.R.
        • Kaplan M.A.
        • Dodd S.L.
        • Kleinman L.
        • Katz N.P.
        • Portenoy R.K.
        Monitoring outcomes during long-term opioid therapy for noncancer pain: Results with the Pain Assessment and Documentation Tool.
        J Opioid Manag. 2005; 1: 257-266
        • Phillips J.E.
        • Bogema S.
        • Fu P.
        • Furmaga W.
        • Wu A.H.B.
        • Zic V.
        • Hammett-Stabler C.
        Signify ER Drug Screen Test evaluation: Comparison to triage drug of abuse panel plus tricyclic antidepressants.
        Clin Chim Acta. 2003; 328: 31-38
        • Portenoy R.K.
        • Farrar J.T.
        • Backonja M.-M.
        • Cleeland C.S.
        • Yang K.
        • Friedman M.
        • Colucci S.V.
        • Richards P.
        Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study.
        Clin J Pain. 2007; 23: 287-299
        • Portenoy R.K.
        Opioid therapy for chronic nonmalignant pain: A review of the critical issues.
        J Pain Symptom Manage. 1996; 11: 203-217
        • Reid M.C.
        • Engles-Horton L.L.
        • Weber M.B.
        • Kerns R.D.
        • Rogers E.L.
        • O'Connor P.G.
        Use of opioid medications for chronic noncancer pain syndromes in primary care.
        J Gen Intern Med. 2002; 17: 173-179
        • Reilly B.M.
        • Evans A.T.
        Translating clinical research into clinical practice: Impact of using prediction rules to make decisions.
        Ann Intern Med. 2006; 144: 201-209
        • Schieffer B.M.
        • Pham Q.
        • Labus J.
        • Baria A.
        • Van Vort W.
        • Davis P.
        • Davis F.
        • Naliboff B.D.
        Pain medication beliefs and medication misuse in chronic pain.
        J Pain. 2005; 6: 620-629
        • Sorensen J.
        • Kalman S.
        • Tropp H.
        • Bengtsson M.
        Can a pharmacological pain analysis be used in the assessment of chronic low back pain?.
        Eur Spine J. 1996; 5: 236-242
      4. Management of Opioid Therapy for Chronic Pain Working Group: VA/DoD Clinical Practical Guidelines for the management of opioid therapy for chronic pain. Contract No: V101(93)P-1633(version 1.0), 2003

        • Toma M.
        • McAlister F.A.
        • Bialy L.
        • Adams D.B.
        • Vandermeer B.
        • Armstrong P.W.
        Transition from meeting abstract to full-length journal article for randomized controlled trials.
        JAMA. 2006; 295: 1281-1287
        • Turk D.C.
        • Swanson K.S.
        • Gatchel R.J.
        Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis.
        Clin J Pain. 2008; 24: 497-508
        • Wasan A.D.
        • Butler S.F.
        • Budman S.H.
        • Benoit C.
        • Fernandez K.
        • Jamison R.N.
        Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.
        Clin J Pain. 2007; 23: 307-315
        • Wasan A.D.
        • Davar G.
        • Jamison R.
        The association between negative affect and opioid analgesia in patients with discogenic low back pain.
        Pain. 2005; 117: 450-461
        • Webster L.R.
        • Webster R.M.
        Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool.
        Pain Med. 2005; 6: 432-442
        • Whiting P.
        • Rutjes A.
        • Reitsma J.
        • Glas A.
        • Bossuyt P.
        • Kleijnen J.
        Sources of variation and bias in studies of diagnostic accuracy: A systematic review.
        Ann Intern Med. 2004; 140: 189-202
        • Wu S.M.
        • Compton P.
        • Bolus R.
        • Schieffer B.
        • Pham Q.
        • Baria A.
        • Van Vort W.
        • Davis F.
        • Shekelle P.
        • Naliboff B.D.
        The addiction behaviors checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain.
        J Pain Symp Manage. 2006; 32: 342-351

      Linked Article